{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "2523634", "DateCompleted": {"Year": "1989", "Month": "06", "Day": "05"}, "DateRevised": {"Year": "2019", "Month": "06", "Day": "26"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0002-8703", "JournalIssue": {"Volume": "117", "Issue": "5", "PubDate": {"Year": "1989", "Month": "May"}}, "Title": "American heart journal", "ISOAbbreviation": "Am Heart J"}, "ArticleTitle": "Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy.", "Pagination": {"StartPage": "1092", "EndPage": "1098", "MedlinePgn": "1092-8"}, "Abstract": {"AbstractText": ["Twenty patients with moderately severe congestive heart failure were randomized to chronic enoximone (n = 10) or placebo (n = 10) therapy in a double-blind manner and serially evaluated over a 16-week-period. The purpose of the study was to determine if the addition of standard doses (1 and 2 mg/kg) of this new phosphodiesterase inhibitor to conventional therapy (digitalis and diuretics) would alter the clinical and laboratory course of this patient population. Except for a transient improvement in the quality of life score, none of the symptomatology indicators were significantly affected by enoximone. Similarly, maximal exercise capacity was not altered. Enoximone did elicit a statistically significant augmentation of echocardiographic, radionuclide angiographic, and systolic time interval parameters of left ventricular function. These enoximone-induced effects were accompanied by a significant increase (7% to 11%) in resting heart rate. Enoximone is capable of improving ventricular function when added to digitalis-diuretic therapy in moderately severe congestive heart failure. While individual patients may benefit from enoximone, the ability of standard doses of this agent to improve symptoms and exercise capacity over a 16-week period appears somewhat limited in a moderately severe heart failure population as a whole. Furthermore, a disparity between improvement in ventricular function parameters and changes in clinical status and exercise performance is apparent in this heart failure population."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Cardiology, Ohio State University College of Medicine, Columbus 43210."}], "LastName": "Leier", "ForeName": "C V", "Initials": "CV"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Binkley", "ForeName": "P F", "Initials": "PF"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Starling", "ForeName": "R C", "Initials": "RC"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Huss-Randolph", "ForeName": "P", "Initials": "P"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Am Heart J", "NlmUniqueID": "0370465", "ISSNLinking": "0002-8703"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Diuretics"}, {"RegistryNumber": "0", "NameOfSubstance": "Imidazoles"}, {"RegistryNumber": "C7Z4ITI7L7", "NameOfSubstance": "Enoximone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Clinical Trials as Topic"}, {"QualifierName": [], "DescriptorName": "Digitalis"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Diuretics"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Enoximone"}, {"QualifierName": [], "DescriptorName": "Exercise Test"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["drug therapy", "physiopathology"], "DescriptorName": "Heart Failure"}, {"QualifierName": ["physiopathology"], "DescriptorName": "Heart Ventricles"}, {"QualifierName": ["drug effects"], "DescriptorName": "Hemodynamics"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Imidazoles"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}, {"QualifierName": [], "DescriptorName": "Random Allocation"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1989", "Month": "5", "Day": "1"}, {"Year": "1989", "Month": "5", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1989", "Month": "5", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["2523634", "10.1016/0002-8703(89)90867-3", "0002-8703(89)90867-3"]}}]}